Journal of Neurology

, Volume 261, Issue 9, pp 1828–1829 | Cite as

Thyroid papillary carcinoma after alemtuzumab therapy for MS

Letter to the Editors

Notes

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare that there is no conflict of interest.

Ethical standard

The authors have complied with the journal’s ethical policies.

References

  1. 1.
    Cohen JA et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828CrossRefPubMedGoogle Scholar
  2. 2.
    Enewold L et al (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18(3):784–791PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Morris LG et al (2013) The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23(7):885–891PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Brito JP, Hay ID, Morris JC (2014) Low risk papillary thyroid cancer. BMJ 348:g3045CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of NeurologySouthmead HospitalBristolUK

Personalised recommendations